
    
      -  To determine overall response rate of patients with low grade neuroendocrine cancer when
           treated with the combination of bevacizumab, pertuzumab and sandostatin LAR®.

        -  To determine the disease control rate (objective response + stable disease), time to
           treatment progression, progression-free survival, and overall survival in patients with
           advanced low grade neuroendocrine cancer when treated with bevacizumab, pertuzumab and
           Sandostatin LAR® treatment.

        -  To define the toxicity and safety of the combination of bevacizumab, pertuzumab and
           Sandostatin LAR® when used in patients with advanced low grade neuroendocrine cancer.
    
  